PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $4.66M |
| Gross Profit (TTM) | $-51.80M |
| EBITDA | $-96.83M |
| Operating Margin | -1798.00% |
| Return on Equity | -30.80% |
| Return on Assets | -10.80% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $12.91 |
| Price-to-Book | 1.34 |
| Price-to-Sales (TTM) | 91.01 |
| EV/Revenue | 35.81 |
| EV/EBITDA | 2.90 |
| Quarterly Earnings Growth (YoY) | 61.50% |
| Quarterly Revenue Growth (YoY) | -38.20% |
| Shares Outstanding | $24.34M |
| Float | $157.18M |
| % Insiders | 0.00% |
| % Institutions | 0.58% |
Volatility is currently contracting
BOSTON--(BUSINESS WIRE)--PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference.
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2025.
BOSTON--(BUSINESS WIRE)--PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange.
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
